Here is an uncomfortable truth sitting in the middle of almost every Triphala supplement label: the compounds listed — gallic acid, ellagic acid, chebulinic acid, quercetin — are not what reaches your target tissues. Most of them are too large, too poorly soluble, or too rapidly metabolised to cross the intestinal epithelium intact. What reaches systemic circulation is something else entirely: a set of smaller, structurally modified metabolites produced not by the plant and not by your body, but by your gut bacteria. Triphala is, in this precise sense, a prodrug formulation. Whether it works at all depends on which microbes you happen to be carrying (Peterson et al., 2020).
What Triphala Actually Contains
Triphala (Sanskrit: tri — three; phala — fruits) is a polyherbal Ayurvedic formulation combining the dried pericarp of three fruits in equal proportion: Phyllanthus emblica (L.) Gaertn. (Amalaki), Terminalia bellerica (Roxb.) (Bibhitaki), and Terminalia chebula (Retz.) (Haritaki). Charaka Samhita, Chikitsa Sthana 1/41–47, classifies Triphala Rasayana as a tridoshic rasayana — a rejuvenative preparation balanced for all three doshas — and attributes to it the capacity to cleanse the srotas (channels), strengthen agni (digestive function), and extend healthy lifespan. The classical formulation encodes a specific doshic logic: Amalaki pacifies Pitta, Bibhitaki addresses Kapha, and Haritaki — called Abhaya (fearless) in Charaka Sutrasthana 25 — balances Vata and provides the primary Rasayana activity.
Phytochemically, Triphala contains over 150 identified bioactive compounds. The dominant polyphenol classes are hydrolysable tannins (including chebulinic acid, chebulagic acid, and punicalagin), gallic acid, ellagic acid (ellagic acid [EA]), and emblicanin A and B (Nasiri et al., 2025). Total phenolic content has been measured at approximately 62.87 ± 0.21 mg gallic acid equivalents per millilitre (mg GAE/mL) in standardised extracts (Kwandee et al., 2023). The critical point is what happens to these compounds after they reach the colon.
The Biotransformation Cascade
Gallic acid — the smallest and most bioavailable of Triphala's phenolics — is absorbed partially in the small intestine and reaches systemic circulation, but a meaningful proportion passes into the colon where Lactobacillus and Bifidobacterium species biotransform it to pyrogallol and other derivatives with distinct anti-inflammatory and antioxidant profiles (Nasiri et al., 2025). More consequential is the fate of ellagic acid (EA), which is the hydrolysis product of ellagitannins and is present in high concentrations in Amalaki and Haritaki.
EA (molecular weight: 302.2 g/mol; log P ≈ 1.6) has poor oral bioavailability in its intact form. In the colon, EA is metabolised by specific anaerobic bacteria through a multi-step dehydroxylation pathway into compounds collectively termed urolithins. Two specialist genera drive this conversion: Gordonibacter urolithinfaciens and Ellagibacter isourolithinifaciens (family Eggerthellaceae), which catalyse lactone-ring cleavage, decarboxylation, and progressive dehydroxylation of EA through a series of intermediate urolithins (M5, M6, C, D) before reaching urolithin A (Uro-A) or urolithin B (Iglesias-Aguirre et al., 2023). A third bacterial species, Enterocloster bolteae (family Lachnospiraceae), acts downstream, converting intermediate Uro-C and IsoUro-A into the final bioactive products Uro-A and Uro-B respectively (Iglesias-Aguirre et al., 2023). No single bacterial species can complete the full conversion alone — it requires this cooperative consortium.
This multi-species dependency explains a clinically important phenomenon: urolithin metabotypes. Population studies consistently identify three groups. Metabotype A (UM-A) individuals — roughly 25–80% of populations studied — carry sufficient Gordonibacter and produce predominantly Uro-A. Metabotype B (UM-B) individuals — 10–50% — carry Ellagibacter and produce a mixture of Uro-A, Uro-B, and isourolithin A (IsoUro-A). Metabotype 0 (UM-0) individuals — 5–25% — carry neither genus and produce no urolithins at all from EA consumption (García-Villalba et al., 2022). Uro-A has demonstrated anti-inflammatory activity, inhibition of colorectal cancer stem cells, improvement of mitochondrial function via mitophagy induction, and enhancement of intestinal barrier integrity; UM-B has been associated with gut microbial dysbiosis and higher colorectal cancer risk in at least one clinical cohort. UM-0 individuals derive none of these benefits regardless of dose.
What the Human and Model Studies Show
The most direct human evidence is a 4-week randomised, double-blind, placebo-controlled pilot trial (randomised controlled trial [RCT]) by Peterson et al. (2020) at the University of California, conducted in 31 healthy adults (Triphala: n=9; placebo: n=11; manjistha comparator: n=9). Participants received 2,000 mg/day of Triphala or comparator. Faecal microbiota profiling by 16S ribosomal ribonucleic acid (rRNA) sequencing detected an average of 336 phylotypes per sample (range: 161–648). The most clinically important finding was not any single bacterial shift but the pattern of response: no taxa were uniformly altered across all Triphala-treated subjects. Responses were highly personalised. Across both herbal treatment groups, the shared trends were a decreased Firmicutes-to-Bacteroidetes (F:B) ratio and increased relative abundance of Akkermansia muciniphila — a mucin-degrading keystone species whose abundance inversely correlates with insulin resistance, obesity, and intestinal permeability in multiple observational cohorts (Peterson et al., 2020).
A 2025 study by Goya-Jorge et al. using the in vitro Simulator of the Human Intestinal Microbial Ecosystem (SHIME®) model — inoculated with faecal microbiota from three women with mild constipation — provided mechanistic detail absent from the human trial. At 2,000 mg/day equivalent dosing over 72 hours, Triphala extract significantly increased Akkermansia muciniphila, consistent with Peterson et al. (2020) and earlier in vitro batch culture data. Metabolic profiling confirmed increased polyphenol-derived metabolites and antioxidant capacity. Ammonia, valeric acid, isovaleric acid, and isobutyric acid — markers of proteolytic fermentation associated with constipation and dysbiosis — were reduced. The Triphala fermentation metabolites enhanced transepithelial electrical resistance (TEER) in a human colon epithelium model, suggesting improved barrier function (Goya-Jorge et al., 2025). An unexpected finding was dose-dependent antagonism of aryl hydrocarbon receptor (AhR) transcriptional activity. AhR signalling regulates intestinal immune homeostasis, and AhR dysregulation is implicated in inflammatory bowel disease (IBD) and colorectal carcinogenesis — antagonism by Triphala polyphenols may represent an anti-inflammatory mechanism independent of direct microbial modulation.
One result from the SHIME study demands direct acknowledgment: Triphala decreased Bifidobacterium spp. in the constipated microbiota model. This contradicts earlier in vitro anaerobic cultivation studies that reported Triphala increased Bifidobacterium (Westfall et al., 2018). The discrepancy is likely context-dependent — Bifidobacterium response may differ between healthy and dysbiotic (constipated) starting microbiomes — but it illustrates that Triphala is not a straightforwardly probiotic substrate. It selects for some taxa at the expense of others, and the net effect depends on baseline microbiome composition.
Triphala's polyphenols reach target tissues as gut bacteria-derived postbiotics, not as the parent compounds listed on any supplement label. The same dose can produce Uro-A (anti-inflammatory, barrier-supportive) in a UM-A individual and nothing bioactive in a UM-0 individual.
The Classical Record, Reassessed
Charaka Samhita, Chikitsa Sthana 1/41–47, describes Triphala Rasayana as a long-term preparation taken with appropriate anupana (carrier substance) — honey for Kapha conditions, ghee for Vata, warm water for Pitta — over weeks to months, not days. The classical instruction to take it consistently for a year for maximum benefit maps more logically onto a microbiome-reshaping intervention than onto a pharmacological drug effect. Microbiome remodelling operates on timescales of weeks; a short course of any polyphenol-rich formulation is unlikely to establish or enrich the bacterial consortia required for full urolithin conversion in a UM-0 individual. The classical Rasayana framing — sustained, low-dose, long-term, carrier-matched — is more biologically appropriate for a prodrug than a drug.
The classical description of Haritaki as Srotoshodhan (channel-cleansing) and Amalaki as the primary Rasayana component align mechanistically: Amalaki is the richest EA source in the formulation, making it the substrate for urolithin production. Haritaki contributes chebulinic acid, whose gut microbial biotransformation product inhibits cyclooxygenase-2 (COX-2) expression — a separate anti-inflammatory pathway confirmed in vitro (Olennikov et al., 2015). The formulation, in other words, is not simply additive; the three fruits provide distinct substrate streams for distinct bacterial bioconversion pathways.
Clinical Implications
There is currently no validated clinical method to determine a patient's urolithin metabotype before prescribing Triphala. Until such testing becomes available, clinicians prescribing Triphala for anti-inflammatory or gut-restorative purposes should treat UM-0 as a plausible outcome in a meaningful minority of patients (5–25%) who will receive no urolithin-mediated benefit regardless of dose or formulation quality. The practical implication is not to abandon Triphala — the AhR antagonism, Akkermansia enrichment, and TEER enhancement observed by Goya-Jorge et al. (2025) are urolithin-independent mechanisms — but to counsel patients that variable response is a biological reality, not a product quality failure. Standardised Triphala extract (minimum 10% tannin content) at 1,000–2,000 mg/day in the evening with warm water, taken for at least 8–12 weeks, represents the evidence-supported protocol. The classical instruction to take it long-term with an appropriate carrier appears mechanistically justified.
What Remains Unanswered
No RCT has enrolled participants stratified by urolithin metabotype before Triphala supplementation and measured both microbiome and downstream inflammatory biomarkers (for example, high-sensitivity C-reactive protein [hs-CRP], faecal calprotectin, or plasma urolithin levels) as co-primary endpoints. Without this design, the clinical significance of the metabotype-dependence cannot be quantified in humans. The Peterson et al. (2020) trial was powered for microbial profiling, not for clinical outcomes — with n=9 per group, it cannot distinguish between individualised response as a biological phenomenon and random noise. A dose-finding RCT establishing the minimum Triphala dose required to shift the F:B ratio and enrich Akkermansia muciniphila in a standardised, reproducible manner in humans with established gut dysbiosis does not yet exist. Finally, whether co-administration of Triphala with probiotic strains carrying Uro-A-producing capacity (for example, Gordonibacter urolithinfaciens or Bifidobacterium pseudocatenulatum) improves urolithin yield in UM-0 individuals — the theoretical basis of synbiotic formulations — has been demonstrated only in animal models, not in human RCTs (Yang et al., 2024).
References
- Peterson CT, Pourang A, Dhaliwal S, Kohn JN, Uchitel S, Singh H, Mills PJ, Peterson SN, Sivamani RK. (2020). Modulatory effects of Triphala and Manjistha dietary supplementation on human gut microbiota: a double-blind, randomized, placebo-controlled pilot study. J Altern Complement Med. 26(11):1015–1024.
- Goya-Jorge E, Aguinaga-Casañas MA, González-Sarrías A, Espín JC, Tomás-Barberán FA, Selma MV, Van de Wiele T, Marzorati M. (2025). Levying evidence of the impact of Triphala in the mildly constipated human colon microbiota. J Funct Foods. 125:106680.
- Iglesias-Aguirre CE, García-Villalba R, Beltrán D, Frutos-Lisón MD, Espín JC, Tomás-Barberán FA, Selma MV. (2023). Gut bacteria involved in ellagic acid metabolism to yield human urolithin metabotypes revealed. J Agric Food Chem. 71(9):4029–4035.
- Nasiri A, Hadi N, Ghafouri-Fard S, et al. (2025). The interplay of Triphala and its constituents with respect to metabolic disorders and gut-microbiome. Fitoterapia. 183:106570.
- Leng P, Wang Y, Xie M. (2025). Ellagic acid and gut microbiota: interactions, and implications for health. Food Sci Nutr. 13:e70133.
- García-Villalba R, Giménez-Bastida JA, Cortés-Martín A, Ávila-Gálvez MÁ, Tomás-Barberán FA, Selma MV, Espín JC, González-Sarrías A. (2022). Urolithins: a comprehensive update on their metabolism, bioactivity, and associated gut microbiota. Mol Nutr Food Res. 66(1):e2101019.
- Charaka, Dridhabala. Charaka Samhita, Chikitsa Sthana 1/41–47 and Sutrasthana 25. In: Sharma PV (Trans. & Ed.). (1998). Chaukhamba Orientalia, Varanasi. Vol. 2.